Alzheimer's Drug Approved by Health Canada
Lecanemab aims to slow early stages of the disease by targeting plaques in the brain.
When someone is diagnosed with dementia, a common fear is losing the ability to stay independent.
The conditional approval of a medication for early Alzheimer's in Canada is being called a positive development.
Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada.
How Lecanemab Works
Lecanemab is a lab-made antibody given by intravenous infusion. It targets the buildup of amyloid plaque in the brain, a hallmark of Alzheimer's disease.
Lecanemab is not a cure and cannot reverse the disease or restore lost memories.
The Alzheimer Society of Canada calls it the first disease-modifying Alzheimer's treatment approved for use in the country.
Author's summary: Lecanemab approved to slow Alzheimer's progression.
More News
- Idaho Farm Bureau Takes Agricultural Education on the Road
- 2025 NBA Cup TRACKER: Scores, Schedule, Standings
- The Week in AgriFoodTech: Fork & Good acquires Orbillion Bio, $100m regen ag fund, Beyond Meat in court
- Humphrey School Students Host First-Ever Minneapolis Mayoral Forum
- Billie Eilish Calls on Billionaires to Do More for People in Need
- Dean Lewis Shares Statement Following Misconduct Allegations
- Stranger Things 5 trailer shows way more than we were ready for
- Kerala Blasters pip Rajasthan Utd 1-0The Shillong Times
- Idaho State History Museum offers free admission to veterans on Veterans Day
- NewJeans to Appeal Label Contract Court Decision